SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Traders are flooding NVDA ahead of its earnings, with sentiment split between those expecting a massive post-earnings rally and those bracing for a sell-the-news drop despite an expected beat. Discussions also highlight concerns over circular financing and Burry's disclosed shorts.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

GRRR is rallying hard after its earnings-triggered selloff, with traders locked in a heated debate over headline losses versus massive revenue growth and 2027 guidance. The community is energized by a higher analyst price target and rising short interest, fueling talk of a potential squeeze as the stock reclaims key technical levels.

Abercrombie & Fitch Co. engages in the retail of apparel, personal care products, and accessories. The firm operates through following geographical segments: Americas, Europe, the Middle East and Africa (EMEA), and Asia-Pacific (APAC). Its brands include Abercrombie and Hollister. The company was founded by David Abercrombie in 1892 and is headquartered in New Albany, OH.

Abercrombie & Fitch Co. - Ordinary Shares - Class A

Abercrombie & Fitch Co.

ANF is surging after a blowout quarter and sharply raised full-year guidance, with chatter focused on a massive short squeeze as traders debate whether momentum stays or fades. The conversation is split between bullish buyback and tariff-refund catalysts versus bearish calls that the spike is a trap.

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Biohaven Ltd

Biohaven Pharmaceutical Holding Company Ltd

BHVN is soaring after licensing its epilepsy drug opakalim to SK Biopharmaceuticals in a deal worth up to $795 million, delivering substantial non-dilutive cash and easing immediate dilution fears. Retail traders are cheering the extended runway and are now shifting their focus to the Phase 2 obesity (taldefgrobep alfa) readout and the broader degrader pipeline as the next major catalysts.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum shares are under pressure after CFO John Markovich announced his retirement, triggering a sharp selloff amid concerns about leadership stability and the company's valuation. The community is split between those seeing a buying opportunity on the dip and those citing weak fundamentals, while broader quantum sector weakness amplifies the decline.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

RVMD is surging on the FDA's approval of its pancreatic cancer drug Rasonque, a first-in-class targeted therapy that nearly doubled median overall survival in a pivotal trial. The community is buzzing over the quick approval timeline and the drug's efficacy data, with many discussing the company's potential as a major oncology player and tying its success to related biotech plays.

SolarEdge Technologies, Inc. engages in the development of energy technology, which provides inverter solutions. The firm operates through the following segments: Solar and All Other. The Solar segment includes the design, development, manufacturing, and sales of an inverter solution designed to maximize power generation. The All Other segment includes the design, development, manufacturing and sales of UPS products, energy storage products, e-Mobility products, and automated machines. Its products and services include photovoltaic inverters, power optimizers, photovoltaic monitoring, software tools, and electric vehicle chargers. The company was founded by Guy Sella, Lior Handelsman, Yoav Galin, Meir Adest, and Amir Fishelov on August 7, 2006 and is headquartered in Herzliya, Israel.

Solaredge Technologies Inc

UBS's upgrade to Buy, citing the FCC's ban on foreign-made network-connected inverters as a potential market share catalyst, is fueling the surge in SEDG conversation. The community is actively debating the bullish implications of this policy shift against the stock's high short interest and the potential for further downside, creating a highly volatile and opinionated discussion.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

OKLO is trending due to a highly polarized social media debate centered on its nuclear/AI catalyst narrative, including the Groves reactor criticality and major partnership agreements, versus persistent bearish arguments about zero revenue, insider selling, and valuation. This tug-of-war is driving extreme volatility, with bulls pointing to execution milestones and long-term AI power demand, while bears highlight the lack of current financials and short-term price drops.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

SMMT is surging after partner Akeso's Phase III HARMONi-GI1 trial showed ivonescimab plus chemo significantly improved overall survival versus durvalumab in first-line advanced biliary tract cancer. Community sentiment is extremely bullish, with traders highlighting this as another validation of ivonescimab's platform potential across multiple tumor types, while others express cautious optimism about the upcoming FDA decision and ongoing dilution. The news reinforces the drug's promise as a potential best-in-class PD-1/VEGF bispecific, strengthening the case for its broader pipeline and near-term regulatory catalyst.

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of therapeutics for metabolic dysfunction-associated steatohepatitis. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.

Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals (MDGL) is surging on renewed buyout speculation, highlighted by a reported large investment and analyst upgrades, with traders buzzing over potential M&A and a strong Q2 beat showing record Rezdiffra sales.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$MNST $CELH $KO Monster Run: This Consumer Stock Turned $1,000 Into $1M Over 22 Years 
https://stocktwits.com/news-articles/markets/equity/monster-run-this-consumer-stock-turned-1-000-into-1-m-over-22-years/cZYkj7GRJ8L

G Money

Matthew

Chase

Monster has outperformed Coca-Cola and Celsius over the past year.

Stocktwits

This Energy Drink Stock Turned $1,000 Into $1M Over Two Decades

StockTwits Web

Monster Beverage Corp.

Celsius Holdings Inc

Coca-Cola Co

 Monster Run: This Consumer Stock Turned $1,000 Into $1M Over 22 Years 


This account has been verified as an official STOCKTWITS representative.